| Log In | Register Now
We restarted a position in Myriad Genetics (MYGN) as a long term "growth at good value" play about 6 weeks ago, despite a horrid technical condition on the chart. Since then the stock has just sort of hung around and done nothing, trading in a very tight range. I was hoping this quarter's earnings report would provide some "oomph" but it appears we have nothing. No need to wait around at this point as the chart looks no better than it did 6 weeks ago and now our catalyst to change that condition has come and gone. At this moment, the stock is simply in a slow downturn and is a better catch for the bears than for bulls.
Boeing Dreamliner Hurdles New Production Hiccup, Flags Higher Output by 2014
Dad Shoots Laptop Video Goes Viral on YouTube After Daughter’s Facebook Rant [VIDEO]
Free Edition
TAKE A TOURWe value your privacy. Your email address will not be shared.
